Although headlines still spray earnings figures all over the media every day, many investors have moved past net earnings as a measure of a company's economic output. That's because earnings are very often less trustworthy than cash flow, since earnings are more open to manipulation based on dubious judgment calls.

Earnings' unreliability is one of the reasons Foolish investors often flip straight past the income statement to eyeball the cash flow statement. In general, by taking a close look at the cash moving in and out of the business, you can better understand whether the last batch of earnings brought money into the company, or merely disguised a cash gusher with a pretty headline.

Calling all cash flows
It's worth checking up on your companies' free cash flow (FCF) once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That brings us to AstraZeneca (NYSE: AZN), which has produced $10.334 billion in FCF over the trailing 12 months (ending March 31), compared to $8.152 billion in net income.



That means that AstraZeneca turned 30% of its revenue into FCF. That looks amazing. Still, it always pays to compare that figure to sector and industry peers and competitors, to see how your company stacks up.

Company

TTM Revenue

TTM FCF

TTM FCF Margin

 GlaxoSmithKline (NYSE: GSK)

 $43,760

 $10,992

25%

 Novartis (NYSE: NVS)

 $48,684

 $12,190

25%

 Roche Holding

 $47,845

 $11,725

24%

 Bristol-Myers Squibb (NYSE: BMY)

 $19,396

 $3,755

19%

 Pfizer (NYSE: PFE)*

 $55,892

 $5,823

10%

 Merck (NYSE: MRK)*

 $33,465

 $2,477

7%

Source: Capital IQ, a division of Standard & Poor's; TTM = trailing 12 months.
*Period ending April 4, 2010 (PFE) and March 31, 2010 (MRK).

Among its competitors and peers, GlaxoSmithKline comes in with the highest FCF margin (defined as FCF/trailing-12-month revenue), with 25% of its revenue turning into FCF. AstraZeneca is well ahead of the pack, as Novartis and Roche Holding also stand at (essentially) 25%, with Bristol-Myers Squibb around 20%. At 10% and less, Pfizer and Merck are currently lagging in FCF production for this cohort.

All cash is not equal
Unfortunately, the cash flow statement isn't immune from nonsense, either. That's why it pays to take a close look at the components of cash flow from operations, to make sure that the cash comes from high-quality sources. They need to be real and replicable in the upcoming quarters, rather than being offset by continual cash outflows that don't appear on the income statement (such as major capital expenditures).

For instance, cash flow based on cash net income and adjustments for non-cash income-statement expenses (like depreciation) is generally favorable. An increase in cash flow based on stiffing your suppliers (by increasing accounts payable) or shortchanging Uncle Sam on taxes will come back to bite investors later. The same goes for decreasing accounts receivable; this is good to see, but it's ordinary in recessionary times, and you can only increase collections so much.

So, how does the cash flow at AstraZeneca look? Take a peek at the chart below, which flags questionable cash flow sources with a red bar.



When I say "questionable cash flow sources," I mean line items such as changes in taxes payable, tax benefits from stock options, and asset sales, among others. That's not to say that companies booking these as sources of cash flow are weak, or are engaging in any sort of wrongdoing, or that everything that comes up questionable in my graph is automatically bad news. But whenever a company is getting more than, say, 10% of its cash from operations from these dubious sources, I feel obliged to crack open the filings and dig even deeper, to make sure I'm in touch with its true cash profitability.

With questionable cash sources composing 13% of the cash flow from operations for AstraZeneca, I think it's time to do a little more digging. Most of the questionable cash flow comes from finance income, which is OK, but it's worth watching for the future.

A Foolish final thought
If you take the time to read past the headlines and crack a filing now and then, you're probably ahead of 95% of the market's individual investors. By keeping an eye on the health of your companies' cash flow, you can spot potential trouble early, or figure out whether the numbers merit Mr. Market's pessimism. Let us know what you think of the health of the cash flows at AstraZeneca in the comments box below. Or, if you're itching to learn more, head on over to our quotes page to view the filings directly.

At the time of publication, Seth Jayson had no position in any company mentioned here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Pfizer is a Motley Fool Inside Value selection. Novartis AG is a Motley Fool Global Gains recommendation. The Fool owns shares of GlaxoSmithKline. The Motley Fool has a disclosure policy.